Olga Evgenievna Zubareva

Dr. Olga Evgenievna Zubareva


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Neuroscience
Verified
Journal Article
Closed access
SMSergey Malkin
Sergey Malkin
DADmitry Amakhin
Dmitry Amakhin
EVEkaterina A. Veniaminova
Ekaterina A. Veniaminova
KKKira Kh. Kim
Kira Kh. Kim
OZOlga Evgenievna Zubareva
Olga Evgenievna Zubareva
AZAleksey Zaitsev
Aleksey Zaitsev

1 October 2019 in Behavioural Brain Research
Verified
Journal Article
Closed access
ISIlya V. Smolensky
Ilya V. Smolensky
OZOlga Evgenievna Zubareva
Olga Evgenievna Zubareva
SKSergey V. Kalemenev
Sergey V. Kalemenev
VLValeria V. Lavrentyeva
Valeria V. Lavrentyeva
ADAlexandra Dyomina
Alexandra Dyomina
AZAleksey Zaitsev
Aleksey Zaitsev

1 November 1999 in Neuroscience
Verified
Journal Article
Closed access
IKI.N. Krasnova
I.N. Krasnova
EBE.R. Bychkov
E.R. Bychkov
VLV.I. Lioudyno
V.I. Lioudyno
OZOlga Evgenievna Zubareva
Olga Evgenievna Zubareva
SDSvetlana Dambinova
Svetlana Dambinova

11 March 2017 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
TPTatyana Y. Postnikova
Tatyana Y. Postnikova
OZOlga Evgenievna Zubareva
Olga Evgenievna Zubareva
AKAnna Kovalenko
Anna Kovalenko
KKK. K. Kim
K. K. Kim
LML. G. Magazanik
L. G. Magazanik
AZAleksey Zaitsev
Aleksey Zaitsev
Cognitive deficits and memory loss are frequent in patients with temporal lobe epilepsy. Persistent changes in synaptic efficacy are considered as a cellular substrate underlying memory processes....

25 October 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ADAlexandra Dyomina
Alexandra Dyomina
OZOlga Evgenievna Zubareva
Olga Evgenievna Zubareva
ISIlya V. Smolensky
Ilya V. Smolensky
DVDmitrii Vasilev
Dmitrii Vasilev
MZMaria Zakharova
Maria Zakharova
AZAleksey Zaitsev
Aleksey Zaitsev
Temporal lobe epilepsy is a widespread chronic disorder that manifests as spontaneous seizures and is often characterized by refractoriness to drug treatment. Temporal lobe epilepsy can be caused by a primary brain injury; therefore, the prevention of epileptogenesis after a primary event is considered one of the best treatment options. However, a preventive treatment for epilepsy still does not exist. Neuroinflammation is directly involved in epileptogenesis and neurodegeneration, leading to the epileptic condition and cognitive decline. In the present study, we aimed to clarify the effect of treatment with a recombinant form of the Interleukin-1 receptor antagonist (anakinra) on epileptogenesis and behavioral impairments in rats using the lithium–pilocarpine model. We found that anakinra administration during the latent phase of the model significantly suppressed the duration and frequency of spontaneous recurrent seizures in the chronic phase. Moreover, anakinra administration prevented some behavioral impairments, including motor hyperactivity and disturbances in social interactions, during both the latent and chronic periods. Histological analysis revealed that anakinra administration decreased neuronal loss in the CA1 and CA3 areas of the hippocampus but did not prevent astro- and microgliosis. The treatment increased the expression level of the solute carrier family 1 member 2 gene (Slc1a2, encoding excitatory amino acid transporter 2 (EAAT2)) in the hippocampus, potentially leading to a neuroprotective effect. However, the increased gene expression of proinflammatory cytokine genes (Interleukin-1β (Il1b) and tumor necrosis factor α (Tnfa)) and astroglial marker genes (glial fibrillary acidic protein (Gfap) and inositol 1,4,5-trisphosphate receptor type 2 (Itpr2)) in experimental rats was not affected by anakinra treatment. Thus, our data demonstrate that the administration of anakinra during epileptogenesis has some beneficial disease-modifying effects.

31 August 2017 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
DADmitry Amakhin
Dmitry Amakhin
SMSergey Malkin
Sergey Malkin
JEJulia L. Ergina
Julia L. Ergina
KKKirill A. Kryukov
Kirill A. Kryukov
EVEkaterina A. Veniaminova
Ekaterina A. Veniaminova
AZAleksey Zaitsev
Aleksey Zaitsev
Temporal lobe epilepsy (TLE) is the most common type of focal epilepsy in humans and is often developed after an initial precipitating brain injury. This form of epilepsy is frequently resistant to pharmacological treatment; therefore, prevention of TLE is the prospective approach to TLE therapy. The lithium-pilocarpine model in rats replicates some of the main features of TLE in human, including the pathogenic mechanisms of cell damage and epileptogenesis after a primary brain injury. In the present study, we investigated changes in the properties of glutamatergic transmission during the first three days after pilocarpine-induced acute seizures in Wistar rats (PILO-rats). Using RT-PCR and electrophysiological techniques, we compared the changes in the temporal cortex (TC) and hippocampus, brain areas differentially affected by seizures. On the first day, we found a transient increase in a ratio of AMPA and NMDA receptors in the excitatory synaptic response in pyramidal neurons of the CA1 area of the dorsal hippocampus, but not in the TC. This was accompanied by an increase in the slope of input-output (I/O) curves for fEPSPs recorded in CA1, suggesting an enhanced excitability in AMPARs in this brain area. There was no difference in AMPA/NMDA ratio in control rats on the third day. We also revealed the alterations in NMDA receptor subunit composition in PILO-rats. The GluN2B/GluN2A mRNA expression ratio increased in the dorsal hippocampus but did not change in the ventral hippocampus or the TC. The kinetics of NMDA-mediated evoked EPSCs in hippocampal neurons was slower in PILO-rats compared with control animals. Ifenprodil, a selective antagonist of GluN2B-containing NMDARs, diminished area and amplitude of evoked EPSCs in CA1 pyramidal cells more efficiently in PILO-rats compared with control animals. These results demonstrate that PILO-induced seizures lead to more severe alterations in excitatory synaptic transmission in the dorsal hippocampus than in the TC. Seizures affect the relative contribution of AMPA and NMDA receptor conductances in the synaptic response and increase the proportion of GluN2B-containing NMDARs in CA1 pyramidal neurons. These alterations disturb normal circuitry functions in hippocampus, may cause neuron damage, and may be one of the important pathogenic mechanisms of TLE.